Non Alcoholic Fatty Liver Disease (NAFLD) Market Treatment, Symptoms, Causes, Pipeline Review, H1 2016
Global Markets Direct's, 'Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2016', provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape. Visit Us @ http://www.radiantinsights.com/research/non-alcoholic-fatty-liver-disease-nafld-pipeline-review-h1-2016
Global Markets Direct's, 'Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2016', provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape.
Visit Us @ http://www.radiantinsights.com/research/non-alcoholic-fatty-liver-disease-nafld-pipeline-review-h1-2016
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>) <strong>Market</strong><br />
<strong>Causes</strong>, Size, Share, <strong>Pipeline</strong> <strong>Review</strong>, <strong>H1</strong> <strong>2016</strong><br />
Summary<br />
Global <strong>Market</strong>s Direct's, '<strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>) - <strong>Pipeline</strong> <strong>Review</strong>, <strong>H1</strong> <strong>2016</strong>', provides<br />
an overview of the <strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>) pipeline landscape.<br />
The report provides comprehensive information on the therapeutics under development for <strong>Non</strong><br />
<strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>), complete with analysis by stage of development, drug target,<br />
mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers<br />
the descriptive pharmacological action of the therapeutics, its complete research and development<br />
history and latest news and press releases. Additionally, the report provides an overview of key players<br />
involved in therapeutic development for <strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>) and features<br />
dormant and discontinued projects.<br />
Click for Report Details @ http://www.radiantinsights.com/research/non-alcoholic-fatty-liverdisease-nafld-pipeline-review-h1-<strong>2016</strong><br />
Global <strong>Market</strong>s Direct's report features investigational drugs from across globe covering over 20 therapy<br />
areas and nearly 3,000 indications. The report is built using data and information sourced from Global<br />
<strong>Market</strong>s Direct's proprietary databases, company/university websites, clinical trial registries,<br />
conferences, SEC filings, investor presentations and featured press releases from company/university<br />
sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic<br />
review following a stringent set of processes to ensure that all the profiles are updated with the latest<br />
set of information. Additionally, various dynamic tracking processes ensure that the most recent<br />
developments are captured on a real time basis.<br />
The report helps in identifying and tracking emerging players in the market and their portfolios,<br />
enhances decision making capabilities and helps to create effective counter strategies to gain<br />
competitive advantage.<br />
Note*: Certain sections in the report may be removed or altered based on the availability and relevance<br />
of data.<br />
Scope
- The report provides a snapshot of the global therapeutic landscape of <strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong><br />
(<strong>NAFLD</strong>)<br />
- The report reviews pipeline therapeutics for <strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>) by companies<br />
and universities/research institutes based on information derived from company and industry-specific<br />
sources<br />
- The report covers pipeline products based on various stages of development ranging from preregistration<br />
till discovery and undisclosed stages<br />
- The report features descriptive drug profiles for the pipeline products which includes, product<br />
description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental<br />
activities<br />
- The report reviews key players involved <strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>) therapeutics and<br />
enlists all their major and minor projects<br />
- The report assesses <strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>) therapeutics based on drug target,<br />
mechanism of action (MoA), route of administration (RoA) and molecule type<br />
- The report summarizes all the dormant and discontinued pipeline projects<br />
- The report reviews latest news related to pipeline therapeutics for <strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong><br />
(<strong>NAFLD</strong>)<br />
Reasons to Buy<br />
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D<br />
strategies<br />
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies<br />
to gain competitive advantage<br />
- Identify and understand important and diverse types of therapeutics under development for <strong>Non</strong><br />
<strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>)<br />
- Identify potential new clients or partners in the target demographic<br />
- Develop strategic initiatives by understanding the focus areas of leading companies<br />
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline<br />
therapeutics<br />
- Devise corrective measures for pipeline projects by understanding <strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong><br />
(<strong>NAFLD</strong>) pipeline depth and focus of Indication therapeutics<br />
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with<br />
the most attractive projects to enhance and expand business potential and Scope<br />
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors<br />
that drove them from pipeline<br />
Browse More <strong>Market</strong> Research Reports @ http://www.radiantinsights.com/catalog/market-researchreports<br />
Table of Contents<br />
Table of Contents 2<br />
List of Tables 7<br />
List of Figures 8<br />
Introduction 9<br />
Global <strong>Market</strong>s Direct Report Coverage 9<br />
<strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>) Overview 10<br />
Therapeutics Development 11
<strong>Pipeline</strong> Products for <strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>) - Overview 11<br />
<strong>Pipeline</strong> Products for <strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>) - Comparative Analysis 12<br />
<strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>) - Therapeutics under Development by Companies 13<br />
<strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>) - Therapeutics under Investigation by Universities/Institutes<br />
15<br />
<strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>) - <strong>Pipeline</strong> Products Glance 16<br />
Late Stage Products 16<br />
Clinical Stage Products 17<br />
Early Stage Products 18<br />
<strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>) - Products under Development by Companies 19<br />
<strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>) - Products under Investigation by Universities/Institutes 21<br />
<strong>Non</strong> <strong>Alcoholic</strong> <strong>Fatty</strong> <strong>Liver</strong> <strong>Disease</strong> (<strong>NAFLD</strong>) - Companies Involved in Therapeutics Development 22<br />
Arisaph Pharmaceuticals, Inc. 22<br />
AstraZeneca Plc 23<br />
Betagenon AB 24<br />
Can-Fite BioPharma Ltd. 25<br />
Conatus Pharmaceuticals Inc. 26<br />
Corcept Therapeutics Incorporated 27<br />
Daewoong Pharmaceutical Co., Ltd. 28<br />
Dimerix Bioscience Pty Ltd 29<br />
Dr. Falk Pharma GmbH 30<br />
Click for Report Details @ http://www.radiantinsights.com/research/non-alcoholic-fatty-liverdisease-nafld-pipeline-review-h1-<strong>2016</strong><br />
About Us:<br />
Radiant Insights Inc. is a platform for companies looking to meet their market research and business<br />
intelligence requirements. We assist and facilitate organizations and individuals procure market<br />
research reports, helping them in the decision making process. We have a comprehensive collection of<br />
reports, covering over 40 key industries and a host of micro markets. In addition to over extensive<br />
database of reports, our experienced research coordinators also offer a host of ancillary services such<br />
as, research partnerships/ tie-ups and customized research solutions.<br />
Contact Details:<br />
Michelle Thoras<br />
Corporate Sales Specialist, USA<br />
Radiant Insights, Inc<br />
28 2nd Street,<br />
Suite 3036 San Francisco,<br />
CA 94105 United States<br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Website: http://www.radiantinsights.com/<br />
Email: sales@radiantinsights.com<br />
Visit our Blog: http://chemicalsandmaterialsri.blogspot.com/
Change language